Trinity Biotech today announced that members of its board of directors acquired a total of 4,501,675 ordinary shares in the company by purchasing stock on the open market and exercising share options.
Chairman and CEO Ronan Ó Caoimh purchased 1,750,800 shares in the open market and exercised 1,070,000 options.
President Brendan Farrell purchased 10,000 shares and exercised 526,875 options. COO Jim Walsh purchased 184,000 shares and exercised 750,000 options.
CFO Rory Nealon exercised 200,000 options and non-executive director Denis Burger purchased 10,000 shares.
Mr Ó Caoimh said: “These transactions reflect the confidence and belief that the senior executives and board of the company have in the future of Trinity Biotech.”
Trinity Biotech is a developer and manufacturer of medical devices, which is listed on the ISEQ and the NASDAQ.